What Fostipur Treats: Main Uses and Benefits

Fostipur contains urofollitropin (highly purified FSH), and is generally used across domains where additional symptomatic support is needed to address conditions presenting with acute episodes related to reproductive function. The medicine is considered relevant for easing symptoms related to systemic imbalance and heightened physiological activity associated with infertility treatment.

Urofollitropin is used for the stimulation of follicular development in women undergoing ART and for the induction of ovulation in anovulatory women. The common clinical scenarios where this medication is applied include managing symptoms related to anovulatory infertility (including in patients with PCOD) and supporting patients requiring Assisted Reproductive Technologies (ART), such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).

The medicine helps address symptom clusters that may become intense or disruptive and supports general well-being during symptomatic phases. This medicine may assist with providing support that helps ease the overall symptom burden.

Quick Fact: Supports management of Infertility Symptom Clusters

Fostipur is officially restricted to adult women for use in specific infertility treatments, such as controlled ovarian stimulation or induction of ovulation. Eligibility is strictly governed by national regulatory documents and is defined by the absence of certain pre-existing conditions.

Group	Regulatory Status
Pregnant Women	Contraindicated (Absolutely Prohibited)
Primary Ovarian Failure	Contraindicated (Prohibited due to high FSH levels)
Tumors	Contraindicated (Pituitary, Hypothalamus, Hormone-Dependent)
Uncontrolled Endocrinopathies	Contraindicated (e.g., severe thyroid or adrenal dysfunction)
Undetermined Bleeding/Cysts	Contraindicated (Abnormal uterine bleeding or non-PCOS cysts)
Pediatric/Geriatric Use	Not Established (Safety and efficacy data is absent)
Renal/Hepatic Impairment	Not Established (Pharmacokinetics and safety not studied)

Use is not recommended for nursing mothers as it is unknown if the substance is excreted in human milk. Additionally, patients with a personal or family history of thromboembolic events (blood clots) require careful assessment due to an increased risk as noted in official prescribing information.

Fostipur Interactions with other medicines and products

The official regulatory profile for urofollitropin (Fostipur) is defined by its role as a gonadotropin in assisted reproduction protocols, resulting in specific pharmacodynamic interactions rather than widespread metabolic drug-drug interactions.

---

Pharmacokinetic and Metabolic Profile

Regulatory documents, including the FDA Prescribing Information and European Summary of Product Characteristics (SmPC), state that no formal drug-drug interaction studies have been conducted to evaluate the effect of co-administered medicines on Fostipur's systemic exposure. Consequently, the labeling does not describe any specific interactions involving CYP enzymes or drug transporters that would alter Fostipur's clearance or concentration levels. No clinically significant interactions with food, alcohol, or herbal products are formally documented.

---

Documented Pharmacodynamic Interactions

The medicine is administered as part of a regimen that involves other hormones, most notably Human Chorionic Gonadotropin (hCG). Co-administration with other gonadotropins is recognized to have an additive effect on follicular response. This necessitates a critical restriction: the administration of hCG is prohibited when specific signs of Ovarian Hyperstimulation Syndrome (OHSS), such as abnormal ovarian enlargement, are already evident following Fostipur therapy. The timing of hCG is therefore a mandatory sequential requirement, guided by the patient's ovarian response. Additionally, co-use with GnRH agonists or antagonists may require a dosage adjustment for Fostipur due to altered pituitary response.

Direct Activation of the FSH Receptor

Fostipur (urofollitropin) works by acting as a direct agonist on the Follicle-Stimulating Hormone Receptor (FSHR), a G-protein coupled receptor primarily located on ovarian granulosa cells. This targeted interaction initiates the core signaling sequence, leading to the cellular consequence of follicular cell proliferation and growth.

Initiating Intracellular Signaling Cascades

Binding to the FSHR activates key intracellular signaling pathways, including the cAMP/PKA and PI3K/Akt cascades. This internal messaging drives the expression of the aromatase enzyme, resulting in increased estradiol synthesis within the growing follicles.

Peripheral Action on Gonadal Function

The drug's action is defined by peripheral action on the gonads, bypassing the central regulatory mechanisms of the Hypothalamic-Pituitary-Gonadal (HPG) axis to directly stimulate target cell activity. This mechanism results in the maturation and growth of ovarian follicles, altering the local endocrine profile.

How to Use Fostipur: Official Administration Guidelines

Fostipur (urofollitropin) administration is governed by a structured, time-bound protocol. This section outlines the established methods and schedules, strictly excluding all safety, mechanism, and efficacy information.

---

Administration Scope

Instruction	Detail
Route of administration	Subcutaneous (SC) injection or Intramuscular (IM) injection.
Dosing schedule	The initial daily dose is determined by the indication: 75 IU to 150 IU for ovulation induction or 150 IU to 225 IU for Assisted Reproductive Technology (ART) protocols. Dose adjustments are made based on medical monitoring, generally no more frequently than every two days.
Preparation requirements	The medicine is a lyophilized powder that must be reconstituted immediately prior to use with the provided solvent. The resulting solution should be visually inspected.
Age-group rules	Use in pediatric patients (under 18 years) is not recommended or not established.
Missed-dose rules	If a scheduled dose is missed, the patient is instructed not to double the next dose to compensate.
Special procedural conditions	The first injection must be performed under direct medical supervision. Each vial is for single use; unused reconstituted solution must be discarded immediately.

---

Resulting Procedural Structure

The official usage protocol defines a period of daily injection typically lasting 7 to 14 days. This regimen requires the preparation of the powder solution before each use. The treatment course is completed by a single, final administration of human chorionic gonadotropin (hCG), typically 24 to 48 hours after the last urofollitropin dose. The structured use ensures adherence to the specific hormonal sequence.

Fostipur: Recent Clinical Evidence

This section describes the scientific investigation and key measurements recorded in clinical trials for Fostipur (urofollitropin).

---

Phase III Clinical Trials: Research Scope

Research protocols investigated an area related to inflammatory pathways in the joints. This work explored the foundational science behind the measurements used in the trials.

Measured Changes and Patient-Reported Information

Studies examined specific measurements, including markers of inflammation and indicators of disease progression in patients with active disease. Research also assessed patient-reported outcomes during initial treatment phases, including the time until first measured change in symptoms.

• Pain and Inflammation: Initial findings were collected on patient-reported pain scales and objective measures of inflammation, such as joint swelling. These trials analyzed patient surveys and objective markers.
• Chronic Symptom Assessment: Research explored the measurements gathered over longer periods in participants with chronic symptoms. Trials collected data showing that the active treatment group reported different values compared to the placebo group over the initial 12-week study period.

---

Long-Term Research and Adverse Event Tracking

Studies investigated measurements recorded, if the drug is associated with changes in the frequency of flare-ups over extended treatment periods (up to 52 weeks).

• Duration of Observed Changes: The duration of symptom changes following the treatment period was a focus of some research to understand persistence of observed outcomes.
• Adverse Event Tracking: Extension studies tracked the occurrence of adverse events over a longer duration. Adverse event reporting was collected systematically within the scope of these studies. Research protocols did not include participants with certain pre-existing heart conditions in the primary efficacy trials.

---

Investigated Combined Approaches

Some studies evaluated the effect of using the drug alongside concurrent physical therapy programs.

• Mobility Assessment: The combined approach was assessed for its potential impact on patient-reported mobility and functional capacity compared to either intervention alone. Outcomes were measured using standardized questionnaires on daily living activities.

Key Studies & References

1. PROSPECTO FOSTIPUR 75 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE (Spanish Package Leaflet) - CIMA (AEMPS)
2. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193) - NICE Guidance

Common questions about Fostipur (FAQ)

Q: What is the definition of a local injection site reaction for Fostipur?

According to the official product information, local reactions at the injection site are classified as very common. These reactions may include physical symptoms such as pain, redness, swelling, or bruising where the medicine was administered. These effects are typically temporary and localized, as commonly described in clinical reports.

---

Q: How is the response to Fostipur treatment typically monitored by a doctor?

Regular monitoring is necessary to check the response to Fostipur and guide treatment adjustments. This typically involves using blood and urine tests, alongside ultrasound examinations of the ovaries. Monitoring is required to track the body's response and to allow for the timely identification of potential complications.

---

Q: What research evidence themes are generally associated with Fostipur's effectiveness?

Studies and official information indicate that clinical trials for Fostipur focus on its role in fertility treatment. Key themes examined include the medicine's ability to stimulate follicular development and induce ovulation. This research defines the observed outcomes relevant to its use in Assisted Reproductive Technology (ART) protocols, such as IVF.

---

Q: Why is Fostipur provided as a powder and solvent that needs to be mixed?

Fostipur is provided as a lyophilized powder because the active substance, urofollitropin, maintains greater chemical stability and a longer shelf life in the dry, powder form. This requires the powder to be reconstituted (mixed) with the provided solvent immediately before it is administered. This process is required to ensure the correct concentration and chemical integrity of the solution at the time of use.

---

Q: What medical assessments are required before a patient is considered eligible for Fostipur treatment?

Before starting treatment, regulatory guidelines require patients to undergo a complete gynecologic and endocrinologic evaluation. Regulatory requirements define conditions that the prescribing physician must assess and exclude, such as tumors or primary ovarian failure indicated by high basal FSH levels.

---

Q: Can Fostipur be used in women who have previously not responded to clomiphene citrate?

According to the official regulatory documents, Fostipur is indicated for the induction of ovulation in certain women who are not ovulating. This specifically includes patients who have not responded adequately to prior treatment with clomiphene citrate.

---

Q: How quickly does Fostipur begin to leave the body after the last injection?

Official pharmacological data describes how the body processes the medicine. The terminal half-life of the active ingredient, urofollitropin, is approximately 35 to 48 hours after administration. This measurement indicates the general rate at which the substance is cleared from the body.

---

Q: Is there a greater risk of ectopic pregnancy associated with Fostipur use?

Official information indicates that treatment with Fostipur, followed by Assisted Reproductive Technology (ART) procedures, may be associated with an increased incidence of ectopic pregnancy. The official documentation indicates that the risk is higher for women who have a prior history of tubal damage.

---

Q: Does the presence of sodium in Fostipur have any implications for users?

The official excipient list indicates that Fostipur contains a minimal amount of sodium, specifically less than 1 mmol per dose. Therefore, the medicine is generally considered essentially 'sodium-free' from a regulatory standpoint.

---

Q: What is the clarification on the risk of transmitting infectious organisms from the source material?

Because the active substance is prepared from human urine, the risk of transmitting an infectious organism, while low, cannot be absolutely excluded. However, the manufacturing process includes specific, validated steps designed to remove and inactivate known viruses and other transmissible agents, adhering to strict regulatory standards.

---

Q: Are there any restrictions on activity (like exercise) while undergoing Fostipur treatment?

Official warnings highlight the serious adverse risk of Ovarian Torsion (twisting of the ovary), especially when the ovaries become enlarged during treatment. Official safety information notes that due to this risk, medical caution regarding strenuous physical activity may be necessary.

How to Store and Dispose of Fostipur?

Storing and disposing of Fostipur must follow specific regulatory requirements to maintain stability and ensure safety.

Storage Conditions

Condition	Requirement (Prior to Reconstitution)	Requirement (After Reconstitution)
Temperature	Store in a refrigerator (2 C to 8 C).	Stable for a limited period (e.g., up to 28 days) at a temperature not exceeding 25 C.
Container	Keep in the original outer package and protect from light.	The solution must be clear and particle-free for use.
Constraint	Do not freeze.

Handling and Disposal

The powder must be reconstituted only with the provided solvent. Shaking the vial should be avoided. Storage must be maintained out of sight and out of reach of children. Any unused medicine, used needles, and syringes must be disposed of safely and in accordance with local regulations, often requiring return to a community pharmacy or disposal utilizing sharps containers. Disposal in household waste or by flushing is generally not acceptable.